AOD-9604 Research Guide: The Lipolytic hGH Fragment

AOD-9604 is what happens when researchers take a 191-amino-acid hormone apart and ask which piece does one specific job. Human growth hormone (hGH) has many actions, and work at Monash University in Australia in the 1990s localized its fat-mobilizing — lipolytic — activity to the hormone's C-terminal end. AOD-9604 is a synthetic, modified copy of that terminal fragment: sixteen amino acids corresponding to residues 176–191 of hGH, with one deliberate change. It was developed as an investigational drug candidate by Metabolic Pharmaceuticals of Melbourne, carried through six randomized controlled trials, and ultimately discontinued as a medicine in 2007. What remains, and what this guide reviews, is its second life as a defined laboratory reagent: its structure, the fragment logic behind it, how it differs from the unmodified fragment it is so often confused with, the development record, and the analytical checks that apply to it.

What Is AOD-9604?

• Identity: a synthetic 16-amino-acid peptide modeled on the C-terminal fragment of human growth hormone, residues 176–191
• Modification: a tyrosine in place of the fragment's native phenylalanine — the change that distinguishes AOD-9604 from plain HGH Fragment 176-191
• Sequence: Tyr–Leu–Arg–Ile–Val–Gln–Cys–Arg–Ser–Val–Glu–Gly–Ser–Cys–Gly–Phe, with a disulfide bridge between the two cysteines
• Molecular weight: approximately 1,815.1 Da
• CAS number: 221231-10-3
• Developer: Metabolic Pharmaceuticals Ltd, Melbourne, Australia
• Status: development as a drug was discontinued in 2007; it is not an approved medicine
• In the NUPEPS PEPTIDES catalog: AOD-9604 10MG, supplied for laboratory research use

The naming deserves one clarification, because two numbering conventions circulate. Most catalog references describe AOD-9604 as fragment 176–191 with a tyrosine substitution; the primary literature also calls it Tyr-hGH177–191, counting the substituted tyrosine as position 1 of a 15-residue native span. The molecule is the same either way: sixteen residues, a tyrosine at the N-terminus where the native fragment carries phenylalanine, and the internal disulfide bridge that the parent hormone's C-terminal region forms. That single substitution is not cosmetic. It is the defined chemical difference between AOD-9604 and the unmodified fragment, and it is why the two are separate catalog items with separate identities — a point the analytical section below returns to.

The Fragment Logic: One Hormone, Separable Activities

The reasoning behind AOD-9604 starts from a structural fact about hGH: a protein's activities are not spread evenly along its length. The growth-promoting actions of hGH are driven mainly by the regions that engage the growth hormone receptor, while a separate body of experimental work — including in-vitro studies in the early 1990s showing that the synthetic C-terminal sequence reproduced intact hGH's antilipogenic activity in adipose tissue — pointed to the C-terminal region as the domain associated with fat metabolism. If those activities are separable, then in principle the fragment alone could reproduce the lipolytic behavior without the receptor-driven growth program of the whole hormone.

That is the hypothesis AOD-9604 was built to test, and its reported pharmacology is consistent with the design: in the published literature the fragment does not act through the growth hormone receptor, and it did not stimulate IGF-1 production in the models studied. For laboratory researchers, this makes AOD-9604 a specific kind of tool — a domain probe. It allows the C-terminal region's behavior to be studied in isolation from the rest of the hormone, in the same way that other fragment reagents let one region of a large protein be examined on its own. It belongs, in the catalog's terms, to the metabolic research area rather than to the growth-hormone-axis category occupied by secretagogues and GHRH analogs, and it should not be conflated with either.

AOD-9604 vs HGH Fragment 176-191

The most common source of confusion around this compound is the near-identical unmodified fragment. HGH Fragment 176-191 is exactly what its name says: the native 176–191 sequence of hGH, phenylalanine first, with no substitutions. AOD-9604 is that fragment with tyrosine in place of the first residue — a change introduced during drug development to improve the molecule's stability profile. The two therefore differ by a single amino acid and by roughly 16 daltons in mass: the unmodified fragment is approximately 1,799 Da, AOD-9604 approximately 1,815 Da. They are close relatives, not synonyms, and a laboratory ordering one while receiving the other has the wrong reagent for any experiment designed around the defined sequence. A dedicated comparison of the two — AOD-9604 vs HGH Fragment 176-191 — is published separately on this site; the point for this guide is that the substitution is AOD-9604's defining feature, and identity testing should be able to prove it is there.

The Development Record, Stated Plainly

AOD-9604's history is unusual among research peptides because it was once a serious pharmaceutical program, and its record is a matter of published trials rather than anecdote. Metabolic Pharmaceuticals advanced the compound through Phase I and Phase II testing as an anti-obesity candidate, running six randomized, double-blind, placebo-controlled trials in total. The outcome is equally a matter of record: in 2007 the company discontinued development after the largest Phase IIb trial did not meet its primary endpoint of statistically significant weight loss against placebo at 24 weeks. No drug application followed, and AOD-9604 is not an approved medicine anywhere.

That history cuts in two directions, and a research guide should hold both. On one side, the compound has a deeper human safety and characterization literature than most laboratory peptides ever acquire — a legacy of its years as an investigational drug. On the other side, the program's own largest and best-controlled test of its headline purpose did not succeed, and that fact belongs in any honest account of the molecule. Neither half converts AOD-9604 into anything other than what it is in the laboratory today: a well-characterized fragment reagent for studying the C-terminal domain of hGH and the adipose-biology questions attached to it, in vitro and in preclinical models.

How Researchers Use It in the Laboratory

Contemporary laboratory use follows the fragment logic. In cell and tissue models, AOD-9604 is used to interrogate the lipolytic pathway attributed to the hGH C-terminus — lipolysis and lipogenesis readouts in adipocyte systems are the classic experimental setting, and the fragment's lack of growth-hormone-receptor activity is precisely what makes the readout interpretable as a domain effect rather than a whole-hormone effect. It is also used as a comparator: experiments that run the fragment beside intact hGH and beside the unmodified 176–191 sequence can separate which behaviors track with the C-terminal domain and which require the rest of the molecule. Work of this kind sits within the broader study of metabolic peptides in weight-management research, where the laboratory questions concern pathways and mechanisms rather than products.

One handling property follows from the structure and recurs in the practical literature: the disulfide bridge. The Cys–Cys bond is part of the molecule's defined conformation, and it is also a chemically reactive feature — reducing conditions can open it, and an opened bridge is a different molecular species with a different mass and different behavior. Storage and handling that protect the bridge, and analytical methods that can see whether it is intact, are therefore part of working with this reagent correctly.

Analytical Verification

Three standard checks apply, each with a molecule-specific reading. Identity by mass spectrometry should confirm the peptide at approximately 1,815.1 Da — and here the check does double duty, because that mass is itself the proof of the defining substitution: the unmodified fragment sits about 16 Da lower, so a correct mass distinguishes AOD-9604 from HGH Fragment 176-191 outright. Purity by HPLC quantifies the intact 16-residue peptide against related impurities, including truncated sequences and material in which the disulfide bridge has been reduced or scrambled — species whose masses and retention behavior differ from the intact compound and which a complete certificate should not hide inside a single purity figure. Net peptide content completes the specification, since lyophilized material includes counter-ion and water mass that a purity percentage alone does not disclose. As with any peptide certificate of analysis, the informative document reports identity, purity, and content for the specific lot in hand.

Frequently Asked Questions

Is AOD-9604 the same as HGH Fragment 176-191? No. AOD-9604 is the modified version of that fragment, with a tyrosine in place of the native phenylalanine — a difference of one amino acid and about 16 Da. They are separate reagents with separate identities.

Does AOD-9604 act through the growth hormone receptor? The published literature reports that it does not, and that it did not raise IGF-1 in the models studied — which is the point of the fragment design: isolating the C-terminal domain's behavior from the whole hormone's receptor-driven activity.

Was AOD-9604 ever a medicine? It was developed as an investigational drug by Metabolic Pharmaceuticals and tested in six randomized controlled trials, but development was discontinued in 2007 after the largest trial missed its primary endpoint. It is not an approved medicine.

How is identity confirmed for a specific lot? By mass spectrometry against the expected mass of approximately 1,815.1 Da, together with HPLC purity and a stated net peptide content — the three-part specification described in the analytical section above and in our guide to reading a peptide COA.